{"url":"https://lda.senate.gov/api/v1/filings/33eb926e-a68d-4099-b7ce-e41dcb14560d/","filing_uuid":"33eb926e-a68d-4099-b7ce-e41dcb14560d","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2025,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/33eb926e-a68d-4099-b7ce-e41dcb14560d/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Catherine Meier","dt_posted":"2025-10-01T11:12:44-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"121 Theory","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Irvine","registrant_state":"CA","registrant_zip":"92617","registrant":{"id":401109834,"url":"https://lda.senate.gov/api/v1/registrants/401109834/","house_registrant_id":77165,"name":"WILLOW LABORATORIES","description":null,"address_1":"121 Theory","address_2":null,"address_3":null,"address_4":null,"city":"Irvine","state":"CA","state_display":"California","zip":"92617","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KAYE MEIER","contact_telephone":"+1 202-525-9066","dt_updated":"2026-03-05T18:01:19.131743-05:00"},"client":{"id":68266,"url":"https://lda.senate.gov/api/v1/clients/68266/","client_id":68266,"name":"WILLOW LABORATORIES","general_description":"technology company","client_government_entity":null,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-08-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Support for funding, coverage and reimbursement for diabetes prevention and wellness technologies; patient safety; support for PBM reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151201,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":null,"last_name":"MEIER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Support for increased Medicare and Medicaid coverage and reimbursement for diabetes prevention technologies; support for CMS TEAM Model [CMMI]","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151201,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":null,"last_name":"MEIER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}